Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DRNANASDAQ:GBIONASDAQ:MORFNYSE:MYOVNYSE:PBH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDRNADicerna Pharmaceuticals$38.22$38.12$19.06▼$40.14$2.99B0.81.34 million shsN/AGBIOGeneration Bio$0.35+3.0%$0.38$0.30▼$3.65$23.33M2.59393,369 shs674,054 shsMORFMorphic$56.99$56.76$19.34▼$57.00$2.85B1.491.27 million shs400 shsMYOVMyovant Sciences$26.98$26.96$7.67▼$27.06$2.62B2.171.17 million shs2.26 million shsPBHPrestige Consumer Healthcare$79.93-0.3%$84.17$64.94▼$90.04$3.95B0.43305,327 shs242,898 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDRNADicerna Pharmaceuticals0.00%0.00%0.00%0.00%0.00%GBIOGeneration Bio+5.59%-7.35%-12.12%-14.99%-85.56%MORFMorphic0.00%0.00%0.00%0.00%+82.19%MYOVMyovant Sciences0.00%0.00%0.00%0.00%0.00%PBHPrestige Consumer Healthcare-0.17%-2.15%-6.28%-5.20%+17.39%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDRNADicerna PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AGBIOGeneration Bio2.9734 of 5 stars3.53.00.00.00.03.31.3MORFMorphic1.0368 of 5 stars1.00.00.04.80.03.30.0MYOVMyovant SciencesN/AN/AN/AN/AN/AN/AN/AN/APBHPrestige Consumer Healthcare4.2381 of 5 stars2.34.00.03.52.91.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDRNADicerna Pharmaceuticals 0.00N/AN/AN/AGBIOGeneration Bio 3.00Buy$7.332,007.28% UpsideMORFMorphic 2.00Hold$57.000.02% UpsideMYOVMyovant Sciences 0.00N/AN/AN/APBHPrestige Consumer Healthcare 2.50Moderate Buy$93.3316.78% UpsideCurrent Analyst Ratings BreakdownLatest DRNA, MORF, MYOV, GBIO, and PBH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025GBIOGeneration BioNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.005/8/2025PBHPrestige Consumer HealthcareRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold4/10/2025GBIOGeneration BioNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDRNADicerna Pharmaceuticals$164.31M18.17N/AN/A$1.84 per share20.77GBIOGeneration Bio$24.56M0.95N/AN/A$1.29 per share0.27MORFMorphic$520K5,490.11N/AN/A$12.31 per share4.63MYOVMyovant Sciences$230.97M11.36N/AN/A($5.04) per share-5.35PBHPrestige Consumer Healthcare$1.14B3.47$5.19 per share15.41$37.04 per share2.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDRNADicerna Pharmaceuticals-$112.75M-$1.63N/AN/AN/A-64.53%-103.08%-16.58%N/AGBIOGeneration Bio-$131.67M-$1.08N/AN/AN/A-292.92%-75.84%-30.40%8/6/2025 (Estimated)MORFMorphic-$152.10M-$3.50N/AN/AN/AN/A-26.62%-25.74%N/AMYOVMyovant Sciences-$205.98M-$1.91N/AN/AN/A-48.47%N/A-39.36%N/APBHPrestige Consumer Healthcare$214.60M$4.2918.6316.792.4118.86%12.87%6.78%8/6/2025 (Estimated)Latest DRNA, MORF, MYOV, GBIO, and PBH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q4 2025PBHPrestige Consumer Healthcare$1.30$1.32+$0.02$1.00$289.36 million$296.52 million5/7/2025Q1 2025GBIOGeneration Bio-$0.25-$0.22+$0.03-$0.22$1.70 million$8.72 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDRNADicerna PharmaceuticalsN/AN/AN/AN/AN/AGBIOGeneration BioN/AN/AN/AN/AN/AMORFMorphicN/AN/AN/AN/AN/AMYOVMyovant SciencesN/AN/AN/AN/AN/APBHPrestige Consumer HealthcareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDRNADicerna PharmaceuticalsN/A2.462.46GBIOGeneration BioN/A8.438.43MORFMorphicN/A24.1324.13MYOVMyovant SciencesN/A1.571.45PBHPrestige Consumer Healthcare0.554.202.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDRNADicerna Pharmaceuticals78.91%GBIOGeneration Bio95.22%MORFMorphic94.25%MYOVMyovant Sciences30.62%PBHPrestige Consumer Healthcare99.95%Insider OwnershipCompanyInsider OwnershipDRNADicerna Pharmaceuticals10.20%GBIOGeneration Bio21.80%MORFMorphic25.60%MYOVMyovant Sciences1.90%PBHPrestige Consumer Healthcare1.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDRNADicerna Pharmaceuticals30278.13 million70.16 millionOptionableGBIOGeneration Bio15067.04 million52.42 millionOptionableMORFMorphic10050.09 million37.27 millionOptionableMYOVMyovant Sciences40797.24 million95.39 millionNot OptionablePBHPrestige Consumer Healthcare54049.42 million48.62 millionOptionableDRNA, MORF, MYOV, GBIO, and PBH HeadlinesRecent News About These CompaniesInvestors in Prestige Consumer Healthcare (NYSE:PBH) have seen impressive returns of 121% over the past five years3 hours ago | finance.yahoo.comWhy Prestige Consumer Healthcare (PBH) is a Top Value Stock for the Long-Term - NasdaqJuly 2 at 11:11 AM | nasdaq.comWhy Prestige Consumer Healthcare (PBH) is a Top Value Stock for the Long-TermJune 30 at 10:46 AM | zacks.comPrestige Consumer Healthcare Inc. (NYSE:PBH) Shares Sold by Allspring Global Investments Holdings LLCJune 28, 2025 | marketbeat.comPrestige Consumer Healthcare Inc. (NYSE:PBH) Receives Average Rating of "Moderate Buy" from AnalystsJune 27, 2025 | marketbeat.comPrestige Consumer Healthcare Inc. (NYSE:PBH) Position Increased by Bessemer Group Inc.June 26, 2025 | marketbeat.comAvior Wealth Management LLC Grows Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)June 22, 2025 | marketbeat.comAdvisor Resource Council Buys Shares of 27,337 Prestige Consumer Healthcare Inc. (NYSE:PBH)June 21, 2025 | marketbeat.comZacks Research Issues Pessimistic Outlook for PBH EarningsJune 19, 2025 | marketbeat.comBoston Trust Walden Corp Sells 12,345 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)June 19, 2025 | marketbeat.comAssenagon Asset Management S.A. Reduces Stock Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)June 19, 2025 | marketbeat.comZacks Research Issues Positive Estimate for PBH EarningsJune 18, 2025 | marketbeat.comMedtech Products Inc. Issues Nationwide Recall of Little Remedies® Honey Cough Syrup Due to Microbial ContaminationJune 17, 2025 | globenewswire.com7,572 Shares in Prestige Consumer Healthcare Inc. (NYSE:PBH) Bought by NorthCrest Asset Manangement LLCJune 15, 2025 | marketbeat.comShould You Continue to Hold Prestige Consumer Stock in Your Portfolio?June 11, 2025 | zacks.comWedge Capital Management L L P NC Trims Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)June 10, 2025 | marketbeat.comPrestige Consumer Healthcare Inc. to Present at the Oppenheimer Annual Consumer Growth and ...June 9, 2025 | gurufocus.comPrestige Consumer Healthcare Inc. to Present at the Oppenheimer Annual Consumer Growth and E-Commerce ConferenceJune 9, 2025 | globenewswire.comOlstein Capital Management L.P. Sells 11,000 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)June 9, 2025 | marketbeat.comPrestige Consumer Healthcare Inc. (NYSE:PBH) Holdings Lowered by Rhumbline AdvisersJune 9, 2025 | marketbeat.comMillennium Management LLC Trims Stake in Prestige Consumer Healthcare Inc. (NYSE:PBH)June 8, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDRNA, MORF, MYOV, GBIO, and PBH Company DescriptionsDicerna Pharmaceuticals NASDAQ:DRNADicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.Generation Bio NASDAQ:GBIO$0.35 +0.01 (+2.99%) As of 03:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Morphic NASDAQ:MORFMorphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Myovant Sciences NYSE:MYOVMyovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.Prestige Consumer Healthcare NYSE:PBH$79.92 -0.26 (-0.32%) As of 02:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
